Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
Vaccination with dendritic cell (DC)/multiple myeloma (MM) fusions has been shown to induce the expansion of circulating multiple myeloma-reactive lymphocytes and consolidation of clinical response following autologous hematopoietic cell transplant (auto-HCT). In this randomized phase II trial (NCT0...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research Jg. 29; H. 23; S. 4784 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.12.2023
|
| Schlagworte: | |
| ISSN: | 1557-3265, 1557-3265 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Vaccination with dendritic cell (DC)/multiple myeloma (MM) fusions has been shown to induce the expansion of circulating multiple myeloma-reactive lymphocytes and consolidation of clinical response following autologous hematopoietic cell transplant (auto-HCT).
In this randomized phase II trial (NCT02728102), we assessed the effect of DC/MM fusion vaccination, GM-CSF, and lenalidomide maintenance as compared with control arms of GM-CSF and lenalidomide or lenalidomide maintenance alone on clinical response rates and induction of multiple myeloma-specific immunity at 1-year posttransplant.
The study enrolled 203 patients, with 140 randomized posttransplantation. Vaccine production was successful in 63 of 68 patients. At 1 year, rates of CR were 52.9% (vaccine) and 50% (control; P = 0.37, 80% CI 44.5%, 61.3%, and 41.6%, 58.4%, respectively), and rates of VGPR or better were 85.3% (vaccine) and 77.8% (control; P = 0.2). Conversion to CR at 1 year was 34.8% (vaccine) and 27.3% (control; P = 0.4). Vaccination induced a statistically significant expansion of multiple myeloma-reactive T cells at 1 year compared with before vaccination (P = 0.024) and in contrast to the nonvaccine arm (P = 0.026). Single-cell transcriptomics revealed clonotypic expansion of activated CD8 cells and shared dominant clonotypes between patients at 1-year posttransplant.
DC/MM fusion vaccination with lenalidomide did not result in a statistically significant increase in CR rates at 1 year posttransplant but was associated with a significant increase in circulating multiple myeloma-reactive lymphocytes indicative of tumor-specific immunity. Site-specific production of a personalized cell therapy with centralized product characterization was effectively accomplished in the context of a multicenter cooperative group study. See related commentary by Qazilbash and Kwak, p. 4703. |
|---|---|
| AbstractList | Vaccination with dendritic cell (DC)/multiple myeloma (MM) fusions has been shown to induce the expansion of circulating multiple myeloma-reactive lymphocytes and consolidation of clinical response following autologous hematopoietic cell transplant (auto-HCT).PURPOSEVaccination with dendritic cell (DC)/multiple myeloma (MM) fusions has been shown to induce the expansion of circulating multiple myeloma-reactive lymphocytes and consolidation of clinical response following autologous hematopoietic cell transplant (auto-HCT).In this randomized phase II trial (NCT02728102), we assessed the effect of DC/MM fusion vaccination, GM-CSF, and lenalidomide maintenance as compared with control arms of GM-CSF and lenalidomide or lenalidomide maintenance alone on clinical response rates and induction of multiple myeloma-specific immunity at 1-year posttransplant.PATIENTS AND METHODSIn this randomized phase II trial (NCT02728102), we assessed the effect of DC/MM fusion vaccination, GM-CSF, and lenalidomide maintenance as compared with control arms of GM-CSF and lenalidomide or lenalidomide maintenance alone on clinical response rates and induction of multiple myeloma-specific immunity at 1-year posttransplant.The study enrolled 203 patients, with 140 randomized posttransplantation. Vaccine production was successful in 63 of 68 patients. At 1 year, rates of CR were 52.9% (vaccine) and 50% (control; P = 0.37, 80% CI 44.5%, 61.3%, and 41.6%, 58.4%, respectively), and rates of VGPR or better were 85.3% (vaccine) and 77.8% (control; P = 0.2). Conversion to CR at 1 year was 34.8% (vaccine) and 27.3% (control; P = 0.4). Vaccination induced a statistically significant expansion of multiple myeloma-reactive T cells at 1 year compared with before vaccination (P = 0.024) and in contrast to the nonvaccine arm (P = 0.026). Single-cell transcriptomics revealed clonotypic expansion of activated CD8 cells and shared dominant clonotypes between patients at 1-year posttransplant.RESULTSThe study enrolled 203 patients, with 140 randomized posttransplantation. Vaccine production was successful in 63 of 68 patients. At 1 year, rates of CR were 52.9% (vaccine) and 50% (control; P = 0.37, 80% CI 44.5%, 61.3%, and 41.6%, 58.4%, respectively), and rates of VGPR or better were 85.3% (vaccine) and 77.8% (control; P = 0.2). Conversion to CR at 1 year was 34.8% (vaccine) and 27.3% (control; P = 0.4). Vaccination induced a statistically significant expansion of multiple myeloma-reactive T cells at 1 year compared with before vaccination (P = 0.024) and in contrast to the nonvaccine arm (P = 0.026). Single-cell transcriptomics revealed clonotypic expansion of activated CD8 cells and shared dominant clonotypes between patients at 1-year posttransplant.DC/MM fusion vaccination with lenalidomide did not result in a statistically significant increase in CR rates at 1 year posttransplant but was associated with a significant increase in circulating multiple myeloma-reactive lymphocytes indicative of tumor-specific immunity. Site-specific production of a personalized cell therapy with centralized product characterization was effectively accomplished in the context of a multicenter cooperative group study. See related commentary by Qazilbash and Kwak, p. 4703.CONCLUSIONSDC/MM fusion vaccination with lenalidomide did not result in a statistically significant increase in CR rates at 1 year posttransplant but was associated with a significant increase in circulating multiple myeloma-reactive lymphocytes indicative of tumor-specific immunity. Site-specific production of a personalized cell therapy with centralized product characterization was effectively accomplished in the context of a multicenter cooperative group study. See related commentary by Qazilbash and Kwak, p. 4703. Vaccination with dendritic cell (DC)/multiple myeloma (MM) fusions has been shown to induce the expansion of circulating multiple myeloma-reactive lymphocytes and consolidation of clinical response following autologous hematopoietic cell transplant (auto-HCT). In this randomized phase II trial (NCT02728102), we assessed the effect of DC/MM fusion vaccination, GM-CSF, and lenalidomide maintenance as compared with control arms of GM-CSF and lenalidomide or lenalidomide maintenance alone on clinical response rates and induction of multiple myeloma-specific immunity at 1-year posttransplant. The study enrolled 203 patients, with 140 randomized posttransplantation. Vaccine production was successful in 63 of 68 patients. At 1 year, rates of CR were 52.9% (vaccine) and 50% (control; P = 0.37, 80% CI 44.5%, 61.3%, and 41.6%, 58.4%, respectively), and rates of VGPR or better were 85.3% (vaccine) and 77.8% (control; P = 0.2). Conversion to CR at 1 year was 34.8% (vaccine) and 27.3% (control; P = 0.4). Vaccination induced a statistically significant expansion of multiple myeloma-reactive T cells at 1 year compared with before vaccination (P = 0.024) and in contrast to the nonvaccine arm (P = 0.026). Single-cell transcriptomics revealed clonotypic expansion of activated CD8 cells and shared dominant clonotypes between patients at 1-year posttransplant. DC/MM fusion vaccination with lenalidomide did not result in a statistically significant increase in CR rates at 1 year posttransplant but was associated with a significant increase in circulating multiple myeloma-reactive lymphocytes indicative of tumor-specific immunity. Site-specific production of a personalized cell therapy with centralized product characterization was effectively accomplished in the context of a multicenter cooperative group study. See related commentary by Qazilbash and Kwak, p. 4703. |
| Author | Chodon, Thinle O'Donnell, Lynn Johnson, Bryon Munshi, Nikhil McKenna, David Avigan, David Karagkouni, Dimitra Howard, Alan Rosenblatt, Jacalyn Ghiasuddin, Haider Lazarus, Hillard M Efebera, Yvonne Geller, Nancy McCarthy, Philip Vlachos, Ioannis S Anderson, Kenneth Soiffer, Robert Uhl, Lynne Pasquini, Marcelo C Shah, Nina Somaiya Dutt, Poorvi Chung, David J Dhakal, Binod Wu, Juan Logan, Brent Malek, Ehsan Rapoport, Aaron P Bisharat, Lina Reese, Jane Devine, Steve Cheloni, Giulia Young, James W Mendizabal, Adam Callander, Natalie Hematti, Peiman Holmberg, Leona Stroopinsky, Dina Nooka, Ajay Waller, Edmund K |
| Author_xml | – sequence: 1 givenname: David J orcidid: 0000-0003-0469-839X surname: Chung fullname: Chung, David J organization: Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 2 givenname: Nina orcidid: 0000-0002-1971-8173 surname: Shah fullname: Shah, Nina organization: University of California San Francisco, San Francisco, California – sequence: 3 givenname: Juan orcidid: 0009-0009-1475-7470 surname: Wu fullname: Wu, Juan organization: Emmes Company, Rockville, Maryland – sequence: 4 givenname: Brent orcidid: 0000-0002-4473-4044 surname: Logan fullname: Logan, Brent organization: Medical College of Wisconsin, Milwaukee, Wisconsin – sequence: 5 givenname: Lina orcidid: 0009-0008-9292-1056 surname: Bisharat fullname: Bisharat, Lina organization: Beth Israel Deaconess Medical Center, Boston, Massachusetts – sequence: 6 givenname: Natalie orcidid: 0000-0002-6975-1086 surname: Callander fullname: Callander, Natalie organization: University of Wisconsin, Madison, Wisconsin – sequence: 7 givenname: Giulia orcidid: 0000-0002-7682-3826 surname: Cheloni fullname: Cheloni, Giulia organization: Beth Israel Deaconess Medical Center, Boston, Massachusetts – sequence: 8 givenname: Kenneth orcidid: 0000-0002-6418-0886 surname: Anderson fullname: Anderson, Kenneth organization: Dana Farber Cancer Institute, Boston, Massachusetts – sequence: 9 givenname: Thinle orcidid: 0009-0000-2307-6209 surname: Chodon fullname: Chodon, Thinle organization: Roswell Park Cancer Institute, Buffalo, New York – sequence: 10 givenname: Binod orcidid: 0000-0002-4377-9742 surname: Dhakal fullname: Dhakal, Binod organization: Medical College of Wisconsin, Milwaukee, Wisconsin – sequence: 11 givenname: Steve orcidid: 0000-0001-7731-759X surname: Devine fullname: Devine, Steve organization: National Marrow Donor Program, Minneapolis, Minnesota – sequence: 12 givenname: Poorvi orcidid: 0000-0002-2802-1300 surname: Somaiya Dutt fullname: Somaiya Dutt, Poorvi organization: Beth Israel Deaconess Medical Center, Boston, Massachusetts – sequence: 13 givenname: Yvonne orcidid: 0000-0002-4163-8823 surname: Efebera fullname: Efebera, Yvonne organization: OhioHealth, Columbus, Ohio – sequence: 14 givenname: Nancy orcidid: 0000-0003-0500-7386 surname: Geller fullname: Geller, Nancy organization: National Lung, Heart and Blood Institute, Rockville, Maryland – sequence: 15 givenname: Haider orcidid: 0009-0008-9495-9429 surname: Ghiasuddin fullname: Ghiasuddin, Haider organization: Beth Israel Deaconess Medical Center, Boston, Massachusetts – sequence: 16 givenname: Peiman orcidid: 0000-0001-5836-4497 surname: Hematti fullname: Hematti, Peiman organization: University of Wisconsin, Madison, Wisconsin – sequence: 17 givenname: Leona orcidid: 0000-0003-3277-1910 surname: Holmberg fullname: Holmberg, Leona organization: Fred Hutchinson Cancer Research Center, Seattle, Washington – sequence: 18 givenname: Alan orcidid: 0009-0003-7273-6906 surname: Howard fullname: Howard, Alan organization: Medical College of Wisconsin, Milwaukee, Wisconsin – sequence: 19 givenname: Bryon orcidid: 0000-0001-7416-3396 surname: Johnson fullname: Johnson, Bryon organization: Medical College of Wisconsin, Milwaukee, Wisconsin – sequence: 20 givenname: Dimitra orcidid: 0009-0007-3961-3399 surname: Karagkouni fullname: Karagkouni, Dimitra organization: Beth Israel Deaconess Medical Center, Boston, Massachusetts – sequence: 21 givenname: Hillard M orcidid: 0000-0002-1159-5607 surname: Lazarus fullname: Lazarus, Hillard M organization: Case Western Reserve University, Cleveland, Ohio – sequence: 22 givenname: Ehsan orcidid: 0000-0003-4719-4327 surname: Malek fullname: Malek, Ehsan organization: Case Western Reserve University, Cleveland, Ohio – sequence: 23 givenname: Philip orcidid: 0000-0002-9577-3879 surname: McCarthy fullname: McCarthy, Philip organization: Roswell Park Cancer Institute, Buffalo, New York – sequence: 24 givenname: David orcidid: 0000-0001-8734-0996 surname: McKenna fullname: McKenna, David organization: University of Minnesota, Minneapolis, Minnesota – sequence: 25 givenname: Adam orcidid: 0009-0002-9742-0329 surname: Mendizabal fullname: Mendizabal, Adam organization: Emmes Company, Rockville, Maryland – sequence: 26 givenname: Ajay orcidid: 0000-0003-4165-6869 surname: Nooka fullname: Nooka, Ajay organization: Emory University, Atlanta, Georgia – sequence: 27 givenname: Nikhil orcidid: 0000-0002-7344-9795 surname: Munshi fullname: Munshi, Nikhil organization: Dana Farber Cancer Institute, Boston, Massachusetts – sequence: 28 givenname: Lynn orcidid: 0000-0002-8123-1884 surname: O'Donnell fullname: O'Donnell, Lynn organization: Ohio State University, Columbus, Ohio – sequence: 29 givenname: Aaron P orcidid: 0000-0003-0043-3562 surname: Rapoport fullname: Rapoport, Aaron P organization: University of Maryland, Baltimore, Maryland – sequence: 30 givenname: Jane orcidid: 0000-0002-0337-5372 surname: Reese fullname: Reese, Jane organization: Case Western Reserve University, Cleveland, Ohio – sequence: 31 givenname: Jacalyn orcidid: 0000-0001-5582-8161 surname: Rosenblatt fullname: Rosenblatt, Jacalyn organization: Beth Israel Deaconess Medical Center, Boston, Massachusetts – sequence: 32 givenname: Robert orcidid: 0000-0002-5810-1192 surname: Soiffer fullname: Soiffer, Robert organization: Dana Farber Cancer Institute, Boston, Massachusetts – sequence: 33 givenname: Dina orcidid: 0009-0006-7359-1560 surname: Stroopinsky fullname: Stroopinsky, Dina organization: Beth Israel Deaconess Medical Center, Boston, Massachusetts – sequence: 34 givenname: Lynne orcidid: 0000-0002-8868-7198 surname: Uhl fullname: Uhl, Lynne organization: Beth Israel Deaconess Medical Center, Boston, Massachusetts – sequence: 35 givenname: Ioannis S orcidid: 0000-0002-8849-808X surname: Vlachos fullname: Vlachos, Ioannis S organization: Beth Israel Deaconess Medical Center, Boston, Massachusetts – sequence: 36 givenname: Edmund K orcidid: 0000-0003-0816-6729 surname: Waller fullname: Waller, Edmund K organization: Emory University, Atlanta, Georgia – sequence: 37 givenname: James W orcidid: 0000-0002-0032-6559 surname: Young fullname: Young, James W organization: Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 38 givenname: Marcelo C orcidid: 0000-0003-1579-2293 surname: Pasquini fullname: Pasquini, Marcelo C organization: Medical College of Wisconsin, Milwaukee, Wisconsin – sequence: 39 givenname: David orcidid: 0000-0003-4624-6017 surname: Avigan fullname: Avigan, David organization: Beth Israel Deaconess Medical Center, Boston, Massachusetts |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37463058$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkNtu1DAQhi1URA_wCKC55CatD3HW4a4ESlfaBVRtuV1N4gk1cuw0doTKy_XVmqqtxNWMRr--b2aO2UGIgRh7L_ipENqcCb4yBS-VPG2aq0KqgkulX7EjofWqULLSB__1h-w4pT-ci1Lw8g07VKuyUlybI3Z_hcHGwf0jCz9vMBGs17CbHHqIPXyhYCeXXQcNeX-2vSMfB4SLObkY4Bd2nQsEf12-gQ0F9O4RZQm26EJeBqEjwD7TBNdjP8WQ4XzO0cffcU5wSQPmOEZHL4JFjCGNHkPG_Gjo4wTb2Wc3-gX6ZP8En7c7aHbfQZRcvGWve_SJ3j3XE3Z98XXXXBabH9_Wzfmm6JSucoF1bazVpm3rVsuaeNXK3phWkqoMSRSl5ZKjrDpUpjUchUEpre1Up7kWvTxhH5-44xRvZ0p5P7jULTtjoOWYvTSqXpWiEmqJfniOzu1Adj9ObsDpbv_ydPkAKoGI6A |
| CitedBy_id | crossref_primary_10_1182_bloodadvances_2023011242 crossref_primary_10_3390_cancers16223867 crossref_primary_10_1016_j_drup_2024_101098 crossref_primary_10_1002_advs_202503238 crossref_primary_10_1080_2162402X_2024_2412876 crossref_primary_10_2147_IJN_S526305 crossref_primary_10_1007_s11060_024_04711_5 crossref_primary_10_1158_1078_0432_CCR_24_2408 crossref_primary_10_1007_s11010_024_04966_6 crossref_primary_10_1186_s40164_024_00576_6 crossref_primary_10_1016_j_heliyon_2024_e27892 crossref_primary_10_1016_j_beha_2025_101650 crossref_primary_10_1016_S0140_6736_25_00553_7 crossref_primary_10_1016_j_canlet_2025_217792 crossref_primary_10_1158_1078_0432_CCR_24_0256 crossref_primary_10_1158_1078_0432_CCR_23_2194 crossref_primary_10_3389_fimmu_2024_1411352 crossref_primary_10_3390_vaccines13080836 crossref_primary_10_3389_fimmu_2024_1527961 |
| ContentType | Journal Article |
| Copyright | 2023 The Authors; Published by the American Association for Cancer Research. |
| Copyright_xml | – notice: 2023 The Authors; Published by the American Association for Cancer Research. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1158/1078-0432.CCR-23-0235 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1557-3265 |
| ExternalDocumentID | 37463058 |
| Genre | Multicenter Study Clinical Trial, Phase II Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: U24 HL138660 – fundername: NHLBI NIH HHS grantid: UG1 HL069249 – fundername: NHLBI NIH HHS grantid: UG1 HL069246 – fundername: NCI NIH HHS grantid: P30 CA008748 – fundername: NHLBI NIH HHS grantid: U10 HL069294 |
| GroupedDBID | --- 18M 29B 2FS 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC ABOCM ACGFO ACIWK ACPRK ADBBV ADNWM AENEX AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P FRP GX1 IH2 KQ8 L7B LSO NPM OK1 P0W P2P QTD RCR RHI RNS SJN TR2 W2D W8F WOQ YKV 7X8 |
| ID | FETCH-LOGICAL-c356t-a998dd58bb9b529e06b2f88b2e368e2a14d020a26ca38b80a18a22ddc3c5051f2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 22 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001154376400014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1557-3265 |
| IngestDate | Fri Sep 05 13:38:59 EDT 2025 Mon Jul 21 05:26:33 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 23 |
| Language | English |
| License | 2023 The Authors; Published by the American Association for Cancer Research. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c356t-a998dd58bb9b529e06b2f88b2e368e2a14d020a26ca38b80a18a22ddc3c5051f2 |
| Notes | SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Undefined-1 content type line 23 ObjectType-Article-3 |
| ORCID | 0000-0002-1971-8173 0009-0009-1475-7470 0000-0002-8849-808X 0000-0003-0469-839X 0000-0002-7344-9795 0000-0002-7682-3826 0009-0008-9292-1056 0000-0002-8868-7198 0000-0002-4377-9742 0000-0002-0337-5372 0009-0007-3961-3399 0000-0003-0043-3562 0000-0002-4163-8823 0000-0003-0500-7386 0000-0003-0816-6729 0000-0003-1579-2293 0000-0002-1159-5607 0009-0006-7359-1560 0000-0002-4473-4044 0000-0001-5582-8161 0009-0000-2307-6209 0009-0003-7273-6906 0000-0002-9577-3879 0000-0003-4624-6017 0000-0002-2802-1300 0009-0008-9495-9429 0000-0002-5810-1192 0000-0003-3277-1910 0000-0003-4719-4327 0000-0001-8734-0996 0000-0001-5836-4497 0000-0002-6418-0886 0000-0003-4165-6869 0000-0002-8123-1884 0000-0002-0032-6559 0000-0002-6975-1086 0009-0002-9742-0329 0000-0001-7731-759X 0000-0001-7416-3396 |
| OpenAccessLink | https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-23-0235/3348372/ccr-23-0235.pdf |
| PMID | 37463058 |
| PQID | 2839741613 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2839741613 pubmed_primary_37463058 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-12-01 |
| PublicationDateYYYYMMDD | 2023-12-01 |
| PublicationDate_xml | – month: 12 year: 2023 text: 2023-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical cancer research |
| PublicationTitleAlternate | Clin Cancer Res |
| PublicationYear | 2023 |
| References | 39350638 - Clin Cancer Res. 2024 Oct 1;30(19):4542. doi: 10.1158/1078-0432.CCR-24-2408. 37733765 - Clin Cancer Res. 2023 Dec 1;29(23):4703-4705. doi: 10.1158/1078-0432.CCR-23-2194. |
| References_xml | – reference: 39350638 - Clin Cancer Res. 2024 Oct 1;30(19):4542. doi: 10.1158/1078-0432.CCR-24-2408. – reference: 37733765 - Clin Cancer Res. 2023 Dec 1;29(23):4703-4705. doi: 10.1158/1078-0432.CCR-23-2194. |
| SSID | ssj0014104 |
| Score | 2.5360298 |
| Snippet | Vaccination with dendritic cell (DC)/multiple myeloma (MM) fusions has been shown to induce the expansion of circulating multiple myeloma-reactive lymphocytes... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 4784 |
| SubjectTerms | Antineoplastic Combined Chemotherapy Protocols - adverse effects Dendritic Cells Dexamethasone - therapeutic use Granulocyte-Macrophage Colony-Stimulating Factor - genetics Hematopoietic Stem Cell Transplantation Humans Lenalidomide - therapeutic use Multiple Myeloma - drug therapy Transplantation, Autologous |
| Title | Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37463058 https://www.proquest.com/docview/2839741613 |
| Volume | 29 |
| WOSCitedRecordID | wos001154376400014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LaxsxEBZNU0IvfT_SF1PodRuvpF1LvZR0W5NA1pjgBN-MntTg7DpxXGj_XP9aZ3ZlcukhkMve9Fg0mvk0I30fY5-GSjgVB8NMRx8z6QKn-m6eRSejcFZ73THenJ8Mx2M1m-lJSrit07XKrU_sHLVvHeXIDzAM6g6Ni6-ry4xUo6i6miQ0dtiuQChDVj2c3VQRZN7JB2LIxI3EyyK94MkLhc6CmGWl4J-r6jTjVMtMim__RZldtBk9vus8n7BHCWfCYW8YT9m90Dxje3WqpD9nf09N49uLxZ_gYfITQxkcH8OUrBHaCN9D4zsNBKjCcnlQ_w7L9sLAaEO5NTg3jjoByuHCSSAoT135ALUh-gni8AjQqY_D2SoSRQIcbjqh3HazhiOiiW1X7SJsB4CeYn1p-ndQDSCShjpddYQ0-hf4Vk-hmo6BTmsv2Nnox7Q6ypKYQ-ZEUV5nBs913hfKWm0LrsOgtDwqZXkQpQrc5NIjcjW8dEYoqwYmV4Zz751wCNLyyF-y-03bhNcMtLFcywEalrRSyMKURgTiahN4zveR77OP26WZ42ahCohpAv7g_GZx9tmrfn3nq57VY46NS3R-6s0tWr9lD0l2vr_W8o7tRnQV4T174H5dL9ZXHzorxO94Uv8D9lzn0w |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Randomized+Phase+II+Trial+of+Dendritic+Cell%2FMyeloma+Fusion+Vaccine+with+Lenalidomide+Maintenance+after+Upfront+Autologous+Hematopoietic+Cell+Transplantation+for+Multiple+Myeloma%3A+BMT+CTN+1401&rft.jtitle=Clinical+cancer+research&rft.au=Chung%2C+David+J&rft.au=Shah%2C+Nina&rft.au=Wu%2C+Juan&rft.au=Logan%2C+Brent&rft.date=2023-12-01&rft.issn=1557-3265&rft.eissn=1557-3265&rft.volume=29&rft.issue=23&rft.spage=4784&rft_id=info:doi/10.1158%2F1078-0432.CCR-23-0235&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1557-3265&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1557-3265&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1557-3265&client=summon |